Biotech NewsCEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022 BioTech Health XSeptember 10, 2022 CEL-SCI recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor… 0 Shares 0 0 0 0 0 0 0
BioTech CEO InterviewsSyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections BioTech Health XSeptember 2, 2022 Our BioTech Health X CEO Series continues with an exclusive interview with Dr. Emil Tsai of SyneuRx. Today… 0 Shares 0 0 0 0 0 0 0